NEW YORK — Agilent Technologies said this week that it has acquired Sigsense Technologies, a San Francisco-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Sigsense technology is already available to Agilent customers through the company's CrossLab Connect, which is used to monitor a wide range of instruments, including chromatography, mass spectrometry, spectroscopy, liquid handlers, plate readers, flow cytometry, centrifuges, NMR, sequencers, and PCR. Integrated into the Agilent CrossLab Connect asset monitoring solution, Sigsense's algorithm tracks instrument utilization and status across all scientific assets, regardless of vendor or manufacturer, Agilent said. Sigsense employees, IP, and assets are now part of the Agilent CrossLab Group. Financial terms of the acquisition were not disclosed.
T2 Biosystems this week reported flat year-over-year revenues for the second quarter of this year. The company booked $2.0 million in revenues in Q2, all from sepsis testing-related products, the same amount as a year ago. A 27 percent increase in sepsis test revenues was offset by declines in international instrument sales. Net loss was $9.2 million, or $.66 per share, compared to a net loss of $6.3 million, or $7.84 per share, in Q2 2023. The Lexington, Massachusetts-based company ended the quarter with $4.2 million in cash and cash equivalents and $551,000 in restricted cash. T2 continues to expect full-year revenues of $10 million to $11 million, all from sepsis products.
Australian molecular diagnostics company Genetic Signatures said this week that it recorded A$4.5 million (US$2.9 million) in sales for its fiscal fourth quarter ended June 30, essentially flat compared to the same quarter a year ago. Quarterly revenues were driven by the resumption of sales of the EasyScreen Respiratory Pathogen Detection Kit following authorization of the revised kit by the Australian Therapeutic Goods Administration. The company said that sales to international markets accounted for approximately 5 percent of overall sales in Q4. Genetic Signatures ended the quarter with A$36.3 million in cash including the proceeds from a A$30 million capital raise completed in July and comprising an institutional placement and a fully underwritten entitlement offer to shareholders. Also, during the quarter, the US Food and Drug Administration granted 510(k) clearance to the company's EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow.
Predictive diagnostics and bioanalytical services company Proteomics International Laboratories this week reported A$148,000 (US$97,000) in revenue for the quarter ended June 30. The Western Australian company ended the quarter with A$6.6 million in cash.
Indian diagnostics and research services firm MedGenome said last month that it has acquired a stake of undisclosed size in GenX Diagnostics, a diagnostic laboratory chain in Odisha, India. GenX maintains seven diagnostic centers and 60 collection centers across the state.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.